Spinal muscular atrophy (SMA) is a genetic neuromuscular disease caused by loss of the SMN1 gene, leading to progressive loss of motor neurons and muscle weakness. The severity ranges from the most serious infant-onset form to milder adult forms, and three disease-modifying therapies approved in recent years have transformed outcomes especially when treatment begins early.
What's actually going on in research
Three therapies — nusinersen, onasemnogene abeparvovec, and risdiplam — are now approved and work by either replacing SMN protein or boosting a backup gene. Trials are testing next-generation gene therapies, combination approaches, and muscle-directed strategies to build on these gains. Research is also focused on treating older and more severely affected patients who responded less to early therapies, and on long-term outcomes after gene replacement.
Next-generation gene therapy
Refined adeno-associated virus gene replacement vectors are being tested to improve delivery and durability in patients who did not receive treatment as infants or who have larger body weights.
Combination SMN strategies
Pairing SMN-boosting drugs such as risdiplam with muscle-directed agents like myostatin inhibitors is being explored to address both motor neuron survival and muscle function simultaneously.
Long-term outcome studies
As the first wave of gene therapy recipients grows older, trials are tracking motor function, respiratory health, and quality of life over years to understand durability and late effects.
What to know before you search
Eligibility depends on SMA type, SMN2 copy number, age, prior treatment history, and current motor function.
What types of trials are currently open
- Gene therapy trials — Testing viral and non-viral approaches to replace or boost SMN protein production.
- SMN-enhancing drug trials — Evaluating small molecules and antisense drugs that increase SMN2 backup gene output.
- Muscle-directed trials — Testing myostatin inhibitors and other agents to strengthen muscles alongside SMN therapy.
- Newborn screening trials — Studying outcomes when SMA is detected and treated at birth before symptoms appear.
- Adult SMA trials — Evaluating treatments in milder adult-onset forms that respond differently to current therapies.
Recently added Spinal Muscular Atrophy trials
Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different areas of the brain to allow adults affected by disabling paralysis (see Eligibility for more details) to control and receive feedback from assistive devices.
HABIT-ILE + FST in Children With SMA: Preliminary Effectiveness
This single-arm pilot study will assess the preliminary effectiveness of an intensive motor skill intervention (HABIT-ILE) combined with functional strength training (FST) in children with SMA who are receiving disease-modifying therapies. Participants will attend a HABIT-ILE + FST summer camp for 6 hours per day over a 3-week period, totaling 90 hours of training.
Find Spinal Muscular Atrophy trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.